
Inclusion: Patients with Inflammatory bowel diasease (histologically confirmed)
Adults 18 years and older
Ability to provide informed consent
Exclusion:
Absolute MRI contraindications
known contrast agent allergy
Determination of IBD severity:
CDAI for Crohn's Disease
SCCAI for Ulcerative colitis
Patients with active disease (n=30)
Patients in remission(n=30)
Cardiovascular MRI
Protocol I
Elevated markers of myocardial inflammation?
Ventricular dysfunction?
Yes
No
Re-Presentation in 5 weeks
Determination of disease severity
Cardiovascular MRI, Protocol II, 5 weeks
Follow-Up after 1 Year
- Determination of disease severity
- Cardiac history (death, CV death, myoacrdial infarction, newly diagnosed heart insuffiency, arrythmias)
- Hospital admissions last year

Protocol I

1. Axial und coronal Overview (T2wTrufi)

2. SSFP-Cine, 2CV, 3CV, 4CV, RV

3. Native T1 mapping, Look-Locker sequence (MOLLI), single breathhold,
   - 1 basal, 1 midventrikulär, 1 apikal (SAX), Schichtdicke: 6 mm, 3 aus 5
   - 4CV

4. Native T2 mapping, T2-preparation steady-state free precession (bSSFP)
   - 1 basal, 1 midventrikulär, 1 apikal (SAX), Schichtdicke: 6 mm, 3 aus 5
   - 4CV

6. Administration Gadolinium contrast agent (Prohance) (Dosing: 0.2 mmol/kgKG)

7. Overview

8. SAX multislice compressed sensing (CS) cine

9. 3D GRE Dixon LGE

10. Post-CA T1-MOLLI-ECV mapping
    - 1 basal, 1 midventrikulär, 1 apikal (SAX), Schichtdicke: 6 mm, 3 aus 5
    - 4CV

1. Axial und coronal Overview (T2wTrufi)

2. SSFP-Cine, 2CV, 3CV, 4CV, RV

3. SAX multislice compressed sensing (CS) cine

4. Native T1 mapping, Look-Locker sequence (MOLLI), single breathhold,
   - 1 basal, 1 midventrikulär, 1 apikal (SAX), Schichtdicke: 6 mm, 3 aus 5
   - 4CV

5. Native T2 mapping, T2-preparation steady-state free precession (bSSFP)
   - 1 basal, 1 midventrikulär, 1 apikal (SAX), Schichtdicke: 6 mm, 3 aus 5
   - 4CV